Biogen Idec (BIIB) and Elan Corporation (ELN) announced results from several studies of TYSABRI that demonstrate its efficacy compared to other multiple sclerosis treatments, provide additional data supporting anti-JC virus antibody status stability, and suggest better outcomes when progressive multifocal leukoencephalopathy is detected early. These data will be presented at the 65th Annual Meeting of the American Academy of Neurology in San Diego. “These new data reinforce our belief in the substantial efficacy TYSABRI has demonstrated at both the early and advanced stages of relapsing forms of MS,” said Alfred Sandrock, M.D., Ph.D., senior vice president, Development Sciences and chief medical officer, Biogen Idec. “We are also encouraged by the consistency in anti-JCV antibody status demonstrated over 18 months, as well as results from our pursuit of additional paths to help mitigate the impact of PML. These combined efforts may allow a more individualized approach when selecting TYSABRI treatment, while helping physicians better understand a patient’s benefit-risk profile.” In an independent statistical analysis led by Timothy Spelman and Helmut Butzkueven, M.D. at the University of Melbourne, with contribution by Fabio Pellegrini and Annie Zhang, TYSABRI demonstrated a significantly lower rate of first relapse compared to interferon beta and glatiramer acetate.